Prolymphocytic leukemia of T-cell type (T-PLL) is a rare and aggressive blood cancer that affects T-cells, a type of white blood cell that helps the body fight infections. T-PLL is a subtype of prolymphocytic leukemia (PLL) and accounts for less than 2% of all cases of leukemia.
T-PLL mostly affects adults, with an average age of diagnosis around 60 years old. The symptoms of T-PLL can vary, but may include enlargement of the lymph nodes, spleen, and liver, fatigue, weakness, and fever.
Treatment for T-PLL can be challenging, as it is an aggressive form of cancer that can spread quickly. The goal of treatment is to control the disease and improve quality of life. Treatment options may include:
Patients with T-PLL may also receive supportive care, such as blood transfusions or antibiotics to prevent infections.
The prognosis for T-PLL can vary depending on the stage of the disease and the patient's overall health. T-PLL is an aggressive cancer that can be difficult to treat, and the five-year survival rate is around 20-30%. However, some patients may respond well to treatment and achieve remission.
T-PLL is a rare and aggressive blood cancer that affects T-cells. Treatment for T-PLL can be challenging, but there are several options available to control the disease and improve quality of life. The prognosis for T-PLL can be poor, but some patients may respond well to treatment and achieve remission.
If you or someone you know has been diagnosed with T-PLL, it is important to seek medical advice from a hematologist/oncologist who specializes in blood cancers.